Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 02/03/2026 at 07:00, 6 months 25 days ago

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach

Schizophrenia Publication Newron Pharmaceuticals Evenamide Adjunctive Treatment
BRIEF

published on 01/07/2026 at 07:05, 7 months 24 days ago

Début d'un essai clinique pour l'événamide au Japon

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Essai De Phase III EA Pharma
BRIEF

published on 01/07/2026 at 07:05, 7 months 24 days ago

Clinical Trial for Evenamide in Japan Commences

Phase III Trial Newron Pharmaceuticals Evenamide Schizophrenia Treatment EA Pharma
PRESS RELEASE

published on 01/07/2026 at 07:00, 7 months 24 days ago

Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai

Schizophrenia Newron Pharmaceuticals Evenamide Phase III EA Pharma
BRIEF

published on 01/06/2026 at 07:05, 7 months 25 days ago

Newron Pharmaceuticals Strengthens IP Portfolio for Evenamide

Patent Schizophrenia Newron Pharmaceuticals Evenamide Glutamate Modulation
BRIEF

published on 01/06/2026 at 07:05, 7 months 25 days ago

Newron Pharmaceuticals renforce son portefeuille de propriété intellectuelle pour Evenamide

Schizophrénie Brevet Newron Pharmaceuticals Evenamide Modulation Du Glutamate
PRESS RELEASE

published on 01/06/2026 at 07:00, 7 months 25 days ago

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Newron Pharmaceuticals obtains new EU Composition of Matter Patent EP4615820 for Evenamide, extending exclusivity into 2044

Patent Intellectual Property Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 12/08/2025 at 07:05, 8 months 23 days ago

Newron lance une étude de phase III aux États-Unis sur l'événamide pour la schizophrénie

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Étude De Phase III
BRIEF

published on 12/08/2025 at 07:05, 8 months 23 days ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
PRESS RELEASE

published on 12/08/2025 at 07:00, 8 months 23 days ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2

Published on 08/31/2026 at 23:30, 49 minutes ago

Datametrex Announces Annual and Special Meeting Voting Results
Published on 08/31/2026 at 23:00, 1 hour 19 minutes ago

Silver Storm Closes Second and Final Tranche of Non-Brokered Private Placement for Aggregate Gross Proceeds of $21.0 Million
Published on 08/31/2026 at 22:55, 1 hour 24 minutes ago

Alset AI Ventures Reports Fiscal Q3 2026 Results, Including $4.1 Million Unrealized, Non-Cash Investment Gain
Published on 08/31/2026 at 22:15, 2 hours 4 minutes ago

Namibia Critical Metals Provides Update on Lofdal Joint Venture Transaction
Published on 08/31/2026 at 22:00, 2 hours 19 minutes ago

NV Gold Announces Closing of First Tranche of Non-Brokered Private Placement

View all ACCESSWIRE

Published on 08/31/2026 at 22:07, 2 hours 12 minutes ago

VIB Vermögen AG with successful Annual General Meeting and effective control and profit transfer agreement
Published on 08/31/2026 at 19:31, 4 hours 48 minutes ago

DEAG reports strong results for the first half of 2026
Published on 08/31/2026 at 19:15, 5 hours 4 minutes ago

CGTN: How China-Kyrgyzstan 'golden' ties deliver for both nations and the region
Published on 08/31/2026 at 19:00, 5 hours 19 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 24 AOUT 2026 au 28 AOUT 2026
Published on 08/31/2026 at 18:20, 5 hours 59 minutes ago

CPI PROPERTY GROUP publishes financial results for the first half of 2026

View all EQS

Published on 08/31/2026 at 18:00, 6 hours 19 minutes ago

MISE A DISPOSITION RAPPORT FINANCIER ANNUEL 2025/2026
Published on 08/31/2026 at 17:45, 6 hours 34 minutes ago

Disclosure of transactions in own shares from August 24 to August 28, 2026
Published on 08/31/2026 at 17:45, 6 hours 34 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 24 au 28 août 2026
Published on 08/31/2026 at 17:45, 6 hours 34 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 08/31/2026 at 17:45, 6 hours 34 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News